Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidon or nintedanib or their switch. Real world data from the EMPIRE registry.
Bildiriler > Özet Bildiri · 2019
Yazarlar: Martina Vasakova, Martina Sterclova, Nesrin MOĞULKOÇ BISHOP, Ka Lawandowska, Veronika Müller, Marta Hajkova, Dragana Jovanovic, Jasna Tekavectrkanjec, Mordechai Kramer, Ma Studnicka, Na Stoeva, Sa Littnerova, Ka Hejduk, La Dusek
ERS International Congress 2019, İspanya, Uluslararası, Poster, Özet Bildiri, 2019-2019, PubMed